Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-MUC1 CAR T and PD-1 Knockout T Cells in Esophageal Cancer
NCT03706326Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Guangdong Pharmaceutical University
- Start
- Sep 2018
- Primary completion
- Sep 2021
- Modality
- Prophylactic Vaccines, Gene Silencing, CRISPR-Cas9
- Countries
- 1
01
Overview
A Phase 2 trial of anti-muc1 car-t cells, PD-1 knockout engineered T cells in esophageal cancer, sponsored by The First Affiliated Hospital of Guangdong Pharmaceutical University. Status: unknown.
02
Drugs
anti-muc1 car-t cellsPD-1 knockout engineered T cells
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03706326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706326.